This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Innovation in science

April 18th, 2010

Results of a study presented today at the International Liver Congress 2010 demonstrate that a dual FXR and TGR5 agonist decreases liver damage and modulates hepatic inflammation and fibrosis in a mouse model of primary sclerosing chlolangitis. In contrast, selective FXR or TGR5 agonists have no beneficial effect.

FXR and TGR5 agonists are responsible for regulating bile acids, glucose, lipids and inflammation.

Primary sclerosing cholangitis (PSC) is a chronic liver disease caused by progressive inflammation and scarring of the bile ducts. Inflammation impedes the flow of bile to the gut, and can ultimately lead to liver cirrhosis, liver failure and liver cancer. The underlying cause of inflammation is thought to be autoimmunity. The definitive treatment is liver transplantation.

Provided by European Association for the Study of the Liver

Citation: Innovation in science (2010, April 18) retrieved 20 August 2026 from https://sciencex.com/wire-news/33049251/innovation-in-science.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.